Author:
Stamova S,Cartellieri M,Feldmann A,Bippes C C,Bartsch H,Wehner R,Schmitz M,von Bonin M,Bornhäuser M,Ehninger G,Rieber E P,Bachmann M
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference8 articles.
1. O’Reilly MK, Paulson JC . Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009; 30: 240–248.
2. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–1496.
3. Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010; 33: 599–608.
4. Baeuerle PA, Kufer P, Bargou R . BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22–30.
5. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955–1962.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献